GSK's chief scientist says an overhaul of the drugmaker's R&D unit has begun delivering results - citing an RSV vaccine and promising hepatitis B and asthma treatments - and pledged a tighter focus than his predecessor on infectious disease and HIV
Today, he said, some 70% of the drugs in the company's development pipeline are "genetically validated", compared with 20% in 2017 before the R&D overhaul began."Hal talked a lot about oncology. I’ll talk less about it," he said, specifying that the R&D focus is now firmly on infectious disease and HIV.
The company sold its marketed cancer drugs to Novartis in 2015 and under Barron's leadership of R&D, sought to rebuild an oncology business, in part through deals like the $5.1 billion purchase in 2019 of U.S. biopharma firm Tesaro. GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. In the case of Zejula,it would limit use of the drug as a second treatment option in consultation with the U.S. Food and Drug Administration , and in line with data on the broader class of therapies that indicated the drugs could have a detrimental effect on survival rates in such patients.
The foray into oncology contributed to negative comparisons by the market to British peer AstraZenecaBarron, who left GSK to lead U.S. biotech start-up Altos Labs but took a seat on GSK's board, declined an interview request for this story. Wood said the R&D team had narrowed its work in oncology to developing treatments for people with advanced states of cancer who are unresponsive to other treatments. He cited ongoing trials for alternate uses for its PD-1 inhibitor drug Jemperli, which is currently approved in the United States and Europe for use on certain types of endometrial cancer.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
When Will We Get an RSV Vaccine?We’re closer than ever, but some people might get it sooner than others.
Leer más »
Woman explains how ex gave her HIV but life has never been better'Being positive doesn't mean you have to be invisible,' Alana Beaumont told Newsweek.
Leer más »
This 19-year-old is capturing what life is like for a young person with HIV'Information is power, so I really wanted to help people understand,' said the college student, who's viral videos attracted over 1.7 million followers on TikTok.
Leer más »
HIV Treatment and Neurologic Data Highlights From CROI 2023Highlights in HIV treatment from CROI2023 focus on injectable and second-line therapies. Top neurologic data include risk factors for stroke and effect of HIV therapy on neurocognitive performance.
Leer más »
Profitable science empowers patientsMajor breakthroughs in medicine, such as treatments for HIV, Hepatitis C, and COVID-19, offer the greatest empowerment to disease-stricken patients who are now able to free themselves of dreadful outcomes from various diseases. Indeed, the ultimate empowerment of a patient with a disease is to make…
Leer más »